GlassScriptPhysician profile
Arnel Paul Guzman
NPI 1811484223
$15,909.64
in general payments reported to CMS, 2019-2025
67 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,933 · 2022: $2,405 · 2023: $3,825 · 2024: $5,563 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,862 · Education: $543 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,862.18 |
| Education | $542.88 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,205.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $966.22 | 2021-2025 | Enhertu, Tagrisso, Imfinzi |
| Merck Sharp & Dohme LLC | $841.22 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $768.89 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $724.09 | 2021-2024 | Reblozyl, Opdualag |
| Genzyme Corporation | $692.53 | 2021-2025 | |
| Pfizer INC. | $683.04 | 2021-2024 | |
| Lilly USA, LLC | $648.13 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $615.72 | 2021-2024 | Xospata, Xtandi, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $552.44 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $520.86 | 2021-2024 | Xpovio |
| Amgen INC. | $482.64 | 2021-2023 | Lumakras |
| Seagen INC. | $469.78 | 2021-2023 | Adcetris, Padcev, Tivdak |
| E.R. Squibb & Sons, L.L.C. | $449.42 | 2021-2024 | Opdivo, Opdualag, Orencia |
| Takeda Pharmaceuticals U.S.A., INC. | $386.36 | 2022-2024 | Fruzaqla, Iclusig, Ninlaro |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $381.46 | 2021-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.41 | 2021-2024 | Gilotrif |
| Janssen Biotech, INC. | $359.94 | 2022-2024 | Erleada, Rybrevant, Tecvayli |
| Eisai INC. | $329.63 | 2021-2024 | |
| Genentech USA, INC. | $291.51 | 2023-2024 | Venclexta, Phesgo, Tecentriq |
| Abbvie INC. | $262.97 | 2022-2025 | |
| Glaxosmithkline, LLC. | $258.84 | 2021-2024 | Zejula, Ojjaara, Jemperli |
| Array Biopharma INC | $248.95 | 2021-2024 | Braftovi, Mektovi, Lorbrena |
| Kite Pharma, INC. | $221.43 | 2021-2024 | Yescarta |
| Exelixis INC. | $183.02 | 2021-2024 | Cabometyx |
| Taiho Oncology, INC. | $172.03 | 2021-2024 | |
| Emd Serono, INC. | $166.25 | 2021-2024 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $163.33 | 2021-2024 | Somatuline Depot, Onivyde |
| Puma Biotechnology, INC. | $162.26 | 2021-2024 | |
| Gilead Sciences, INC. | $148.69 | 2021-2024 | |
| Beigene USA, INC. | $129.50 | 2021-2024 | Brukinsa |
| Pharmaessentia USA Corporation | $124.56 | 2023-2024 | Besremi |
| Immunogen, INC. | $114.06 | 2023-2024 | Elahere, Elahere |
| Daiichi Sankyo INC. | $110.19 | 2023-2025 | Enhertu |
| Sobi, INC | $109.99 | 2024 | |
| Sun Pharmaceutical Industries INC. | $102.37 | 2023-2024 | Yonsa |
| Tersera Therapeutics LLC | $101.90 | 2023-2024 | Zoladex |
| Coherus Oncology, INC. | $101.32 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Deciphera Pharmaceuticals INC. | $94.42 | 2022-2024 | Qinlock |
| Genmab U.S., INC. | $91.20 | 2023-2024 | Epkinly |
| Immunocore Limited | $73.21 | 2024 | Kimmtrak |
| Adc Therapeutics America, INC. | $64.01 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $61.36 | 2021-2023 | Libtayo |
| Tolmar Pharmaceuticals, INC. | $58.54 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $55.89 | 2022 | |
| Alexion Pharmaceuticals, INC. | $55.80 | 2021-2024 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $53.92 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $47.26 | 2021-2023 | |
| Morphosys, US INC. | $44.78 | 2023 | Monjuvi |
| Organon LLC | $42.57 | 2022-2024 | |
| Mirati Therapeutics, INC. | $41.48 | 2024 | Krazati |
| Myovant Sciences INC. | $40.53 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $38.75 | 2021 | |
| Alnylam Pharmaceuticals INC. | $37.31 | 2023 | Givlaari |
| Stemline Therapeutics INC. | $36.25 | 2023 | Orserdu |
| Springworks Therapeutics, INC. | $29.86 | 2024 | Ogsiveo |
| Foundation Medicine, INC. | $28.98 | 2022 | |
| Pharmacosmos Therapeutics INC. | $28.92 | 2024 | Monoferric |
| Heron Therapeutics, INC. | $27.77 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $26.01 | 2024 | Clonoseq |
| Sumitomo Pharma America, INC. | $20.48 | 2023 | Orgovyx |
| Octapharma USA, INC. | $18.76 | 2023 | Panzyga |
| Chiesi USA, INC. | $18.57 | 2024 | Ferriprox |
| Epizyme, INC. | $17.99 | 2022 | |
| Spectrum Pharmaceuticals INC. | $13.55 | 2023 | Rolvedon |
| Ge Healthcare | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnel Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.